Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday

Motley Fool2021-10-14

Key Points An infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil. Aviptadil is in development for the treatment of respiratory ...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

MengYang
2021-10-15
MengYang
Like please
aiyohyun
2021-10-14
aiyohyun
Ok
- aiyohyun:
  ok
new_money
2021-10-14
new_money
I see, good
kevinlaisq
2021-10-14
kevinlaisq
Pls like
CLOUD1127
2021-10-14
CLOUD1127
Ok
alexsander
2021-10-14
alexsander
damn

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1151136903?lang=zh_CN&edition=full","thumbnail":"","is_english":true,"pubTime":"2021-10-14 23:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151136903","market":"us","top_or_hot":-1,"title":"Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday","media":"Motley Fool","content":"<div>\n<p>Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">网页链接</a>\n\n</div>\n","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Why NRx Pharmaceuticals Stock Is Jumping Again on Thursday</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nWhy NRx Pharmaceuticals Stock Is Jumping Again on Thursday\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-10-14 23:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory ...</p>\n\n<a href=\"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NRXP","symbol_name":"NRX Pharmaceuticals Inc.","start_time":0,"source_url":"https://www.fool.com/investing/2021/10/14/why-nrx-pharmaceuticals-is-jumpng-again-on-thursda/","article_id":"1151136903","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151136903","pubTimestamp":1634225065,"columns":[],"sourceInfo":null,"weMediaInfo":null,"summary":"New clinical trial results bode well for aviptadil in treating critically ill COVID-19 patients.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"NRXP":"NRX Pharmaceuticals Inc."},"translate_title":"为什么NRx制药公司的股票在周四再次上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NRXP":0.9},"content_text":"Key Points\n\nAn infectious-disease journal published results from a clinical trial with NRx Pharmaceuticals' lead candidate aviptadil.\nAviptadil is in development for the treatment of respiratory failure related to severe COVID infection.\nThe peer-reviewed results were positive but hardly sufficient to support a request for Emergency Use Authorization from the FDA.\n\nWhat happened\nShares of NRx Pharmaceuticals(NASDAQ:NRXP) are rising sharply for the second time this week. On Tuesday, the stock jumped higher after the company relayed some positive regulatory developments. Today, investors are excited about clinical trial results for aviptadil, a potential new treatment for respiratory failure caused by COVID-19. The biotech stock was up 33.8% as of 10:54 a.m. EDT on Thursday.\nSo what\nThis morning, an infectious-disease journal published peer-reviewed results of an open-label trial with aviptadil and critically ill COVID patients. An impressive 81% of patients treated with aviptadil survived at least 60 days compared to just 21% of patients given standard care.\nIMAGE SOURCE: GETTY IMAGES.\nThe number of severe COVID infections has dropped considerably since the study, but there could still be enough to drive significant sales. As a clinical-stage company without any approved drugs generating revenue, even modest sales of aviptadil could lead to market-beating gains for NRx Pharmaceuticals investors.\nNow what\nUnfortunately, we still don't know when NRx Pharmaceuticals will get a chance to launch aviptadil. The results presented today are interesting, but there's more work to do.\nToday's announcement came from an open-label trial conducted in a single hospital system without any randomization. Investigators simply treated 21 consecutive eligible patients who were admitted to a single hospital system in Houston during the summer of 2020.\nIn place of a placebo, investigators used patients with similar comorbidities admitted before and after the group who were treated with aviptadil. These results are interesting. On their own, though, they won't be sufficient to support an Emergency Use Authorization request.","kind":"news","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[{"id":825465331,"gmtCreate":1634255457263,"gmtModify":1634274405899,"author":{"id":"3575113315907312","authorId":"3575113315907312","name":"MengYang","avatar":"https://static.tigerbbs.com/2dece979ff56347c710918e7aa49d224","vip":1,"crmLevel":4,"crmLevelSwitch":0,"idStr":"3575113315907312","authorIdStr":"3575113315907312"},"htmlText":"Like please","listText":"Like please","text":"Like please","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825465331","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":825234430,"gmtCreate":1634226446182,"gmtModify":1634226446334,"author":{"id":"3582936698066263","authorId":"3582936698066263","name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3582936698066263","authorIdStr":"3582936698066263"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":1,"repostSize":0,"link":"https://laohu8.com/post/825234430","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"comments":[{"id":6199692,"gmtCreate":1634226451787,"gmtModify":1634635729217,"authorId":3582936698066263,"author":{"id":3582936698066263,"idStr":"3582936698066263","authorId":3582936698066263,"name":"aiyohyun","avatar":"https://static.tigerbbs.com/5efe05924fc38dd8db647c314e32c5b2","vip":1,"crmLevel":1,"crmLevelSwitch":0,"individualDisplayBadges":[]},"repliedAuthorId":0,"objectId":825234430,"type":1,"supId":0,"prevId":0,"content":"<u>ok</u>","text":"<u>ok</u>","html":"<u>ok</u>"}],"langContent":"CN"},{"id":825232679,"gmtCreate":1634226272357,"gmtModify":1634226272444,"author":{"id":"4093757289971380","authorId":"4093757289971380","name":"new_money","avatar":"https://static.tigerbbs.com/11c53e8b0bc90836e57b9dbd4236a68a","vip":1,"crmLevel":2,"crmLevelSwitch":0,"idStr":"4093757289971380","authorIdStr":"4093757289971380"},"htmlText":"I see, good","listText":"I see, good","text":"I see, good","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825232679","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":825239032,"gmtCreate":1634225919860,"gmtModify":1634225920053,"author":{"id":"3572874548548490","authorId":"3572874548548490","name":"kevinlaisq","avatar":"https://static.tigerbbs.com/329de1199f764a89b7cadf50308e183d","vip":1,"crmLevel":1,"crmLevelSwitch":0,"idStr":"3572874548548490","authorIdStr":"3572874548548490"},"htmlText":"Pls like","listText":"Pls like","text":"Pls like","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825239032","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":825295415,"gmtCreate":1634225715740,"gmtModify":1634225715852,"author":{"id":"3584019054184037","authorId":"3584019054184037","name":"CLOUD1127","avatar":"https://static.laohu8.com/default-avatar.jpg","vip":1,"crmLevel":5,"crmLevelSwitch":0,"idStr":"3584019054184037","authorIdStr":"3584019054184037"},"htmlText":"Ok","listText":"Ok","text":"Ok","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825295415","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"},{"id":825299625,"gmtCreate":1634225352004,"gmtModify":1634225363930,"author":{"id":"4093485445879440","authorId":"4093485445879440","name":"alexsander","avatar":"https://static.tigerbbs.com/74729d318355ddcc28103cafe6b6d677","vip":1,"crmLevel":3,"crmLevelSwitch":0,"idStr":"4093485445879440","authorIdStr":"4093485445879440"},"htmlText":"damn","listText":"damn","text":"damn","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"link":"https://laohu8.com/post/825299625","repostId":1151136903,"repostType":4,"isVote":1,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"tweetType":1,"langContent":"CN"}],"isCommentEnd":false,"newsSizeData":{"likeSize":42,"commentSize":7,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1151136903"}